176 related articles for article (PubMed ID: 15645997)
21. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
22. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
23. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
24. Understanding niacin formulations.
Pieper JA
Am J Manag Care; 2002 Sep; 8(12 Suppl):S308-14. PubMed ID: 12240702
[TBL] [Abstract][Full Text] [Related]
25. A case for immediate-release niacin.
Bassan M
Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
[TBL] [Abstract][Full Text] [Related]
26. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
[TBL] [Abstract][Full Text] [Related]
27. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
28. Antiatherothrombotic effects of nicotinic acid.
Rosenson RS
Atherosclerosis; 2003 Nov; 171(1):87-96. PubMed ID: 14642410
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
30. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
32. The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
Ito MK
Ann Pharmacother; 2004 Feb; 38(2):277-85. PubMed ID: 14742767
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
34. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
Jacobson TA
Curr Atheroscler Rep; 2001 Sep; 3(5):373-82. PubMed ID: 11487448
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
36. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
37. New perspectives on the use of niacin in the treatment of lipid disorders.
McKenney J
Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
[TBL] [Abstract][Full Text] [Related]
38. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
39. Treating mixed dyslipidemias: why and how.
Ballantyne CM
Clin Cardiol; 2001; 24(7 Suppl):II-6-9. PubMed ID: 11444652
[TBL] [Abstract][Full Text] [Related]
40. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
